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Capsule summary:  Group 2 innate lymphoid cells (ILC2s) are upstream regulators of IL-5-dependent 15 
eosinophil function in asthma.  We’ve shown that ILC2s do not express the IL-5R and thus IL-5R-16 
dependent therapeutic interventions (e.g. Benralizumab) are unlikely to be mediated directly on 17 
ILC2s. 18 
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Abbreviations: 26 
IL-5 - Interleukin-5 27 
IL-5Rα – Interleukin-5 receptor α-subunit 28 
ILC2s – Group 2 innate lymphoid cells 29 
GMFI – geometric mean fluorescence intensity 30 
SED – Super enhanced Dmax 31 
 32 
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Words – main text 1087 33 
Human Group 2 innate lymphoid cells do not express the IL-5 receptor 34 
To the Editor, 35 
Eosinophils, cardinal effector cells of type-2 inflammation, contribute to the clinical and 36 
immunopathological manifestations of asthma1 and COPD2 inflammatory endotypes.  Eosinophil 37 
biology is governed by Interleukin (IL)-5, a cytokine that binds with high affinity to a specific IL-5 38 
receptor α-subunit (IL-5Rα) prior to forming a heterodimeric receptor complex with the β- subunit 39 
(βc)3.  IL-5 signalling promotes differentiation, maturation and survival of eosinophil committed 40 
progenitors whilst acting on mature eosinophils to enhance their migratory potential and effector 41 
responses4. IL-5 signalling also promotes alternative splicing of the IL-5Rα gene to generate 42 
transmembrane forms of IL-5Rα5. Since the IL-5-IL-5R axis appears to be restricted to eosinophils 43 
and basophils (and their progenitors)6, therapeutic regulation of these cells through the neutralisation 44 
of circulating IL-5 (e.g. mepolizumab and reslizumab)1 or IL-5Rα ligation (e.g. Benralizumab)1, 2, 45 
have emerged as effective strategies to deplete blood, tissue and airway eosinophils and consequently 46 
reduce exacerbation rates and improve lung function1.   47 
Basophils and Group 2 innate lymphoid cells (ILC2s) are important innate sources of type-2 48 
cytokines, including IL-5, in response to epithelial derived cytokines such as IL-337, 8.  Group 2 innate 49 
lymphoid cells (ILC2s), however, have emerged as central and critical innate co-ordinators of steady 50 
state eosinophilopoiesis and epithelial cell driven, type 2 immunopathology in asthma8.  As an 51 
important upstream regulator of eosinophil function we asked whether ILC2s, like their basophil 52 
counterparts, express the IL-5Rα sub-unit since this may have important implications for our 53 
understanding of the role of the IL-5-IL-5R axis in disease and therapeutic targeting of these rare but 54 
important innate immune cells.  Detailed methods are provided in the online repository. 55 
ILC2s are rare innate lymphocytes that lack the T cell receptor complex and all known lineage 56 
markers but, similar to other type 2 cytokine producing cells such as Th2 cells, eosinophils and 57 
basophils, express the type 2 prostaglandin D2 receptor, DP2/CRTh2 (CD294)9.  We defined blood 58 
ILC2s as cells with singlet, lymphocyte light scatter properties (Fig 1A-B), lineage (CD2, 3, 14, 16, 59 
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19, 56 and 235a)- but CD294+ (Fig 1C).  A large proportion of cells within this gate were basophils, 60 
(CD123+ cells in Fig 1D), however, CD294+, CD123- ILC2s were present (Fig 1D and light scatter in 61 
E).  Basophils displayed a higher level of CD125-PE staining than the ILC2s (Fig 1D) that could be 62 
blocked in the presence of rhIL-5 (Fig 1F), confirming the specificity of the antibody and basophil IL-63 
5Rα expression.  In contrast to basophils, there was no change in CD125-PE signal intensity when 64 
ILC2s were incubated with rhIL-5 indicating that there was no IL-5Rα expression on these cells (Fig 65 
1F).  To confirm the reproducibility of these findings, we recruited 6 control and 13 volunteers with 66 
asthma in each group (clinical details in Table E1 of the online repository) and measured IL-5Rα 67 
expression.  The total mean (SD) % of ILC2s within the lymphocyte gate for both control and asthma 68 
groups were 0.1±0.1% and 0.03±0.03%, respectively (p=0.06, Mann Whitney).  In total, combining 69 
asthma and control data sets, the basophil CD125 geometric mean fluorescence intensity (GMFI) 70 
(mean±SD) in the absence or presence of rhIL-5 was 1285±614 and 401±315 respectively, 71 
representing a significant reduction in GMFI (Fig 1G and I).  In contrast, the ILC2 CD125 GMFI 72 
(mean±SD) in the absence or presence of rhIL-5 were 45±45 and 42±33, respectively (Fig 1H and I).  73 
In a subset of samples (n=3), where basophils and ILC2s could be detected in whole blood, data were 74 
qualitatively similar.  There were no significant differences between the control and asthma subjects 75 
for any of the flow cytometric measurements obtained. 76 
 77 
We next sought to confirm whether the IL-5Rα data was reflected at the RNA level using real-time 78 
PCR probes spanning the exon boundaries present within IL-5Rα subunit variants (Fig E1A).  For 79 
this, ILC2s were isolated from 3 additional donors and cultured in the absence or presence of 80 
cytokines known to enhance survival (IL-2 and IL-7) and activate ILC2s (IL-25 and IL-33).  RNA 81 
was isolated at 6 time points (Day 0, 1, 2, 4, 7 and 14) and converted into cDNA.  Eosinophil cDNA 82 
was included as a positive control.  The IL-5Rα transcripts were not detected in ILC2s at any time 83 
point, however, an increase in IL-5 mRNA was observed indicating that the culture conditions were 84 
sufficient to activate the cells (Fig E1 B and C). 85 
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Finally, using a similar approach to the blood analyses (Fig 1) and utilising surgically removed lung 86 
tissue from 7 subjects (Table E2) we asked whether tissue-derived ILC2s and basophils expressed IL-87 
5Rα.  Tissue-derived basophils were defined as viable, CD45+Lin-CD294+CD123+CD127- cells and 88 
ILC2s as viable, CD45+Lin-CD294+CD123-CD127+ cells present within the singlet lymphocyte gate 89 
(Fig 2A-E).  Basophil CD125-PE GMFI (612±327 mean±SD) could be reversed in the presence of 90 
rhIL-5 to a mean(±SD) of 317±91 (example in Fig 2F and cumulative data in 2H).  Using the super 91 
enhanced Dmax (SED) algorithm to compare basophil populations stained in the absence or presence 92 
of IL-5 for each of the 7 donors, revealed that 71.1±4.2% (mean±SD) basophils were CD125 positive 93 
(Fig 2I).  In contrast,  ILC2 CD125 GMFI (mean±SD) was significantly lower than basophils and 94 
showed little change in the presence of rhIL-5 (190±42 and 145±49, respectively) (example in Fig 2G 95 
and cumulative data in 2H).  SED analysis of ILC2s stained in the absence or presence of rhIL-5 for 96 
each of the 7 donors (Fig2I) did not reveal a CD125 positive subset (mean±SD 3.3±0.89%). Data 97 
from these 7 subjects consistently show that tissue-derived basophils express the IL-5Rα whereas 98 
tissue-derived ILC2s do not (Fig 2H).   99 
The strength(s) of this study lies in the fact that we have measured protein IL-5Rα subunit expression 100 
in a rare critical regulator of type 2 inflammation, ILC2s, and in the context of rhIL-5 mediated 101 
receptor blockade/downregulation, rather than an isotype control which is less robust.  The robustness 102 
of our data using human peripheral blood (from asthmatic donors), ex vivo activated cells and lung 103 
tissue cells diminishes the likelihood that IL-5Rα expressing ILC2s are present in asthmatic tissue. 104 
Although it would be desirable to extend our blood and tissue observations to investigate whether 105 
ILC2s in bronchial biopsies from asthmatics express IL-5Rα the paucity of tissue ILCs and the need 106 
for multiple immunological markers to positively identify them severely limits this approach.  These 107 
results extend the list of cells6 that are known not to express the IL-5Rα subunit, specific for the 108 
biological activities of IL-5.  Moreover, we show that rare tissue derived basophils, like their blood 109 
counterparts, express the IL-5Rα. Our data suggest that the success of therapeutic interventions 110 
targeting IL-5/R are unlikely to be mediated directly on ILC2s but may function via both eosinophils 111 
and basophils. 112 
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 150 
Figure 1 CD125 protein is absent on blood ILC2s.  A, total PBMCs, singlets within boxed region. B, 151 
singlet light scatter with lymphocyte gate overlaid. C, lineage-, CD294+ cells were identified (boxed 152 
region) encompassing D, CD123+ basophils and CD123- ILC2s, in the upper and lower left quadrant, 153 
respectively with GMFI values. E, ILC2 light scatter properties are shown. F, Overlay of basophil and 154 
ILC2 CD125 stained cells in the absence (red) or presence (blue) of rhIL-5.  G, basophil and H, ILC2 155 
CD125 GMFI paired data (mean±SD) from 6 healthy (open) and 13 asthma (filled) volunteers, also 156 
shown in I, unpaired on the same axes.  Statistical comparisons were made using a Wilcoxon 157 
matched-pairs signed rank test.  158 
 159 
Figure 2 CD125 protein is absent on lung derived ILC2s.  A, total lung tissue cells, singlets within 160 
boxed region. B, singlet light scatter properties with lymphocyte gate overlaid. C, viable CD45+ cells 161 
(boxed region). D, shows lineage- CD294+ cells (boxed region). E, ILC2s (CD123-CD127+) and 162 
basophils (CD123+CD127-) were identified. F, depicts basophil CD125 fluorescence and G, ILC2 163 
CD125 fluorescence in the absence (red) or presence of rhIL-5 (blue). H, Collated basophil and ILC2 164 
CD125 GMFI (mean±SD) data (n=7).  I, Proportion of CD125+ basophils and ILC2s (calculated using 165 
SED), exemplar values given in F and G. Statistical comparisons were made using a Wilcoxon 166 
matched-pairs signed rank test.   167 
 168 
 169 
 170 
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